Position statement on the use of biosimilars in inflammatory bowel disease
Biologics are effective and have a good safety profile in the treatment of inflammatory bowel disease. Biosimilars have recently become available as treatment option. They are biological agents that are highly similar to the original biologic compound in their structure, biological activity, effic...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SMW supporting association (Trägerverein Swiss Medical Weekly SMW)
2019-12-01
|
| Series: | Swiss Medical Weekly |
| Subjects: | |
| Online Access: | https://www.smw.ch/index.php/smw/article/view/2696 |
| _version_ | 1811194325511438336 |
|---|---|
| author | Emanuel Burri Pascal Juillerat Michel H. Maillard Michael Manz Pierre Michetti Christian Mottet Gerhard Rogler Nadine Zahnd Stephan Vavricka |
| author_facet | Emanuel Burri Pascal Juillerat Michel H. Maillard Michael Manz Pierre Michetti Christian Mottet Gerhard Rogler Nadine Zahnd Stephan Vavricka |
| author_sort | Emanuel Burri |
| collection | DOAJ |
| description |
Biologics are effective and have a good safety profile in the treatment of inflammatory bowel disease. Biosimilars have recently become available as treatment option. They are biological agents that are highly similar to the original biologic compound in their structure, biological activity, efficacy and safety. This position paper summarises current knowledge on biosimilars and presents its statements on regulatory issues and clinical situation in order to provide clinicians adequate information for them to reach informed and appropriate shared decision-making with their patients.
|
| first_indexed | 2024-04-12T00:25:07Z |
| format | Article |
| id | doaj.art-134f2a90e4e340839cef28d0a0e3e0c0 |
| institution | Directory Open Access Journal |
| issn | 1424-3997 |
| language | English |
| last_indexed | 2024-04-12T00:25:07Z |
| publishDate | 2019-12-01 |
| publisher | SMW supporting association (Trägerverein Swiss Medical Weekly SMW) |
| record_format | Article |
| series | Swiss Medical Weekly |
| spelling | doaj.art-134f2a90e4e340839cef28d0a0e3e0c02022-12-22T03:55:33ZengSMW supporting association (Trägerverein Swiss Medical Weekly SMW)Swiss Medical Weekly1424-39972019-12-01149495010.4414/smw.2019.20148Position statement on the use of biosimilars in inflammatory bowel diseaseEmanuel Burri0Pascal Juillerat1Michel H. Maillard2Michael Manz3Pierre Michetti4Christian Mottet5Gerhard Rogler6Nadine Zahnd7Stephan Vavricka8Gastroenterologie und Hepatologie, Medizinische Universitätsklinik, Kantonsspital Baselland, Liestal, SwitzerlandGastroenterologie, Universitätsklinik für Viszerale Chirurgie und Medizin, Bauchzentrum Bern, Inselspital, Bern, SwitzerlandGastroentérologie Beaulieu SA, Lausanne ; and Service de Gastroentérologie et Hépatologie, Département de Médecine Interne, Centre Hospitalier Universitaire Vaudois, Lausanne, SwitzerlandClarunis – Universitäres Bauchzentrum Basel, SwitzerlandGastroentérologie Beaulieu SA, Lausanne ; and Service de Gastroentérologie et Hépatologie, Département de Médecine Interne, Centre Hospitalier Universitaire Vaudois, Lausanne, SwitzerlandCentre Sédunois de Gastroentérologie, Sion, SwitzerlandKlinik für Gastroenterologie und Hepatologie, Universitätsspital Zürich, SwitzerlandCenterview GmbH, Zürich, SwitzerlandZentrum für Gastroenterologie und Hepatologie AG, Zürich, Switzerland Biologics are effective and have a good safety profile in the treatment of inflammatory bowel disease. Biosimilars have recently become available as treatment option. They are biological agents that are highly similar to the original biologic compound in their structure, biological activity, efficacy and safety. This position paper summarises current knowledge on biosimilars and presents its statements on regulatory issues and clinical situation in order to provide clinicians adequate information for them to reach informed and appropriate shared decision-making with their patients. https://www.smw.ch/index.php/smw/article/view/2696biologicsbiosimilarsinflammatory bowel disease |
| spellingShingle | Emanuel Burri Pascal Juillerat Michel H. Maillard Michael Manz Pierre Michetti Christian Mottet Gerhard Rogler Nadine Zahnd Stephan Vavricka Position statement on the use of biosimilars in inflammatory bowel disease Swiss Medical Weekly biologics biosimilars inflammatory bowel disease |
| title | Position statement on the use of biosimilars in inflammatory bowel disease |
| title_full | Position statement on the use of biosimilars in inflammatory bowel disease |
| title_fullStr | Position statement on the use of biosimilars in inflammatory bowel disease |
| title_full_unstemmed | Position statement on the use of biosimilars in inflammatory bowel disease |
| title_short | Position statement on the use of biosimilars in inflammatory bowel disease |
| title_sort | position statement on the use of biosimilars in inflammatory bowel disease |
| topic | biologics biosimilars inflammatory bowel disease |
| url | https://www.smw.ch/index.php/smw/article/view/2696 |
| work_keys_str_mv | AT emanuelburri positionstatementontheuseofbiosimilarsininflammatoryboweldisease AT pascaljuillerat positionstatementontheuseofbiosimilarsininflammatoryboweldisease AT michelhmaillard positionstatementontheuseofbiosimilarsininflammatoryboweldisease AT michaelmanz positionstatementontheuseofbiosimilarsininflammatoryboweldisease AT pierremichetti positionstatementontheuseofbiosimilarsininflammatoryboweldisease AT christianmottet positionstatementontheuseofbiosimilarsininflammatoryboweldisease AT gerhardrogler positionstatementontheuseofbiosimilarsininflammatoryboweldisease AT nadinezahnd positionstatementontheuseofbiosimilarsininflammatoryboweldisease AT stephanvavricka positionstatementontheuseofbiosimilarsininflammatoryboweldisease |